Harmony Biosciences Holdings, Inc.
NASDAQ: HRMY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeffrey Dayno
- Employees
- 268
- Headquarters
- Plymouth Meeting, United States
- IPO year
- 2020
- Market cap
- $2.0B
- Website
- https://www.harmonybiosciences.com
Loading HRMY…
Loading profile data…Frequently asked questions about HRMY
What does Harmony Biosciences Holdings, Inc. (HRMY) do?
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with...
Where does HRMY trade?
Harmony Biosciences Holdings, Inc. (HRMY) trades on the NASDAQ Global Market.
What sector is HRMY in?
Harmony Biosciences Holdings, Inc. (HRMY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Harmony Biosciences Holdings, Inc.?
Jeffrey Dayno is the chief executive officer of Harmony Biosciences Holdings, Inc. (HRMY).
Where is Harmony Biosciences Holdings, Inc. headquartered?
Harmony Biosciences Holdings, Inc. is headquartered in United States.
Does HRMY pay a dividend?
Harmony Biosciences Holdings, Inc. (HRMY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HRMY go public?
Harmony Biosciences Holdings, Inc. (HRMY) completed its initial public offering in 2020.